{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:51:53Z","timestamp":1792461113645,"version":"4.5.0"},"reference-count":27,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IDR"],"DOI":"10.2147\/idr.s423004","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T07:45:06Z","timestamp":1706687106000},"page":"343-354","source":"Crossref","is-referenced-by-count":7,"title":["In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020"],"prefix":"10.2147","volume":"Volume 17","author":[{"given":"Marie","family":"Kempf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Arhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Kuraieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-3069","authenticated-orcid":true,"given":"Eric","family":"Utt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"859935","DOI":"10.3389\/fcimb.2022.859935","volume":"12","author":"Dunbar","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13756-018-0398-x","volume":"7","author":"Zhu","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"832007","DOI":"10.3389\/fmed.2022.832007","volume":"9","author":"Duan","year":"2022","journal-title":"Front Med Lausanne"},{"key":"ref5","first-page":"1","volume":"63","author":"Diekema","year":"2019","journal-title":"Antimi Agen Chem"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cmi.2019.11.001","volume":"26","author":"Giannella","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1093\/cid\/ciw828","volume":"64","author":"Doernberg","year":"2017","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2049936119863013","DOI":"10.1177\/2049936119863013","volume":"6","author":"Quinn","year":"2019","journal-title":"Ther Adv Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40121-013-0010-x","volume":"2","author":"Shirley","year":"2013","journal-title":"Infect Dis Ther"},{"key":"ref11","unstructured":"TEFLARO\u00ae (ceftaroline fosamil) for injection, for intravenous use. 2022. Available from: https:\/\/www.rxabbvie.com\/pdf\/teflaro_pi.pdf. Accessed 22, December 2022."},{"key":"ref12","unstructured":"Pfizer. Zinforo 600 mg powder for concentrate for solution for infusion: summary of product characteristics. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zinforo-epar-product-information_en.pdf. Accessed 22, December, 2022."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/jac\/dku085","volume":"69","author":"Tattevin","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1128\/AAC.02371-13","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimi Agen Chem"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ijid.2020.11.130","volume":"102","author":"Sader","year":"2021","journal-title":"Int J Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.diagmicrobio.2016.01.010","volume":"85","author":"Sader","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref18","unstructured":"Antimicrobial Testing Leadership and Surveillance (ATLAS). 2022. Available from: https:\/\/atlas-surveillance.com\/. December 18, 2022."},{"key":"ref19","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Wayne, PA: Clinical and Laboratory Standards Institute; 2018."},{"key":"ref20","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute; 2022."},{"key":"ref21","unstructured":"EUCAST. Breakpoint tables for interpretation of MICs and zone diameters; 2023."},{"key":"ref22","unstructured":"Pfizer. Tygacil. Package insert. 2022. Available from: https:\/\/www.pfizer.com\/products\/product-detail\/tygacil. Accessed December 21, 2022."},{"key":"ref23","unstructured":"EUCAST. Ceftaroline S. aureus breakpoints revised: addendum (July 2017) to EUCAST breakpoint tables v. 7.1. 2023. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Addenda\/Addendum_2017-07-14.pdf. Accessed 12, October 2023."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.2147\/IDR.S226649","volume":"12","author":"Zhang","year":"2019","journal-title":"Infect Drug Resist"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijid.2018.10.004","volume":"77","author":"Sader","year":"2018","journal-title":"Int J Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"114843","DOI":"10.1016\/j.diagmicrobio.2019.05.015","volume":"95","author":"Bae","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jgar.2021.04.020","volume":"26","author":"Pierard","year":"2021","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Infection and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=96362","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=96362","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T07:45:16Z","timestamp":1706687116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/in-vitro-activity-of-ceftaroline-against-isolates-of-gram-positive-bac-peer-reviewed-fulltext-article-IDR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":27,"URL":"https:\/\/doi.org\/10.2147\/idr.s423004","relation":{},"ISSN":["1178-6973"],"issn-type":[{"value":"1178-6973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}